Hide Board Information

Show Board Information

Synthesis Energy Systems Inc. SYNE

Board Mod: Add me as mod

Asst Mods:

Last Post: 01/02/2020 7:39:44 PM

Board Marks: 0

Posts Today: 0

Board Views Today: 4

Synthesis Energy Systems Inc. (NASDAQ: SYNE) Stock Message Board

1. SYNE Company Profile

    

2. SYNE Time & Sales

    

3. SYNE Recent News

    

4. SYNE Filings

    

5. SYNE Financials

    

6. SYNE Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

7	SES 100% v17M c11.4 f1,3M had a strong floor	znewcar1	01/02/2020 7:39:44 PM
6	$SES up 86% pre market on a Pr at 6:20 Am Report (1)	PoemStone	01/02/2020 9:25:37 AM
5	SES Pre Market RUSH!???	znewcar1	01/02/2020 1:22:13 AM
4	SES 18% v865K c8.90 f1,3M H9.99	znewcar1	11/08/2019 6:23:40 PM
3	SES 26% v5,M c9.20 f1,3M found S@7ish yesterday	znewcar1	10/17/2019 4:15:29 PM
2	SES 271% v32M c19.50 f1,3M H26.1 S@18 what a run	znewcar1	10/14/2019 4:06:15 PM
1	SES 191% v31M c5.25 f1,3M WOW what a ride! Gap up	znewcar1	10/11/2019 4:19:30 PM

Recent Articles

• Diversified Energy Company Moves to Primary U.S. Listing
• Yiren Digital Partners with ChainUp for Blockchain Expansion
• Understanding the C3.ai Class Action and Your Options as an Investor
• Essential Consumer Trends and Brand Innovations You Can't Miss
• Minesto Engages in Strategic Collaboration with South Korea
• RoboUP's Raccoon 2 SE: The Affordable Smart Lawn Solution
• Erayak Power Solution Group Inc. Launches U.S. Subsidiary for Growth
• Latest Innovations in Health: Key Press Releases This Week
• CCTV Market Growth Driven by Security Concerns and Innovation
• Global Net Lease Receives Investment-Grade Upgrade From Fitch Ratings
• Harvia Plc Declares Exciting New Dividend for Shareholders
• Mawson Infrastructure Group Reports Positive Developments in Q3
• AKVA Group ASA's Strategic Buyback Program for Shares
• Viktor Orbán Initiates Preparations for Peace Summit Talks
• Stellantis and Pony AI Collaborate on Electric Vans for Europe
• Exploring the Vibrant Highlights of Fashion Week in Xiamen
• Investigation into F5 Inc: Alert for Investors and Witnesses
• Grainger's Strategic Shift: Divesting Cromwell for Growth
• CSX Corp Sees Significant Share Increase Amid Strong Earnings
• Market Outlook: Financial Stocks Drive Down Futures, Key Players React
• AEON Revolutionizes Payments in Georgia with QR Technology
• Grainger's Strategic Shift: Divesting Cromwell for Growth Focus
• Hyperscale Data Announces New Dividends and Future Plans
• Projected Growth of Magnesium Oxide Market to $6.31 Billion
• Highlights from This Week's Noteworthy Press Releases
• B2PRIME Expands Institutional Footprint with New Leadership
• Molina Healthcare Investors: Take Action Against Losses Now
• Minesto Strengthens Ties with South Korea for Ocean Energy
• Kelun-Biotech Celebrates Approval of Trastuzumab Botidotin
• XAG Celebrates FAO Award for Innovative Farming Solutions
• Adhesion Barrier Market Forecast: Growth Driven by Innovation
• UCLOUDLINK Partners with AHAM AL TAFASIL for PetPhone Launch
• US Cobalt Tender Cancellation Signals New Industry Strategies
• Tech Giants Shift Manufacturing Out of China Amid Tensions
• Exciting New Listing of ZEROBASE (ZBT) on Bybit Spot Trading
• SEMIFIVE Moves Toward KOSDAQ Listing with Exciting Prospects
• Huawei Introduces Revolutionary AI WAN Solution for Carriers
• John Bolton's Indictment Raises Questions of Accountability
• Huawei's New AI WAN Technology Empowers Carriers for Growth
• Octopus AIM VCT plc Set to Launch New Subscription Offer
• Zhihu Inc. Launches Yanyan Story at Frankfurt Book Fair
• TriEye Revolutionizes Military Mobility with Innovative Vision Tech
• Qustodio: The Ultimate Parental Control App for Families
• New Oriental Education Announces Annual Meeting for Shareholders
• Rebecca Rau Jewels Introduces Unique Collection of Art and Design
• Salama's Capital Restructuring Strengthens Financial Stability
• Experience a New Standard of Wellness at Life Time's Club
• ITM to Highlight Innovations in Neuroendocrine Tumor Treatment
• AKYNZEO® Outperforms Traditional Treatments for CINV
• TOLREMO Therapeutics Advances Cancer Treatment with TT125-802